Top Industry Leaders in the Thymus Cancer Market
Novartis drug Afinitor (everolimus) received FDA approval in combination with chemotherapy for advanced unresectable thymic carcinoma, offering a new treatment option for patients.
Amgen drug Blincyto (blinatumomab) is being investigated in a Phase 2 clinical trial for relapsed or refractory thymic carcinoma, potentially expanding its therapeutic applications.
AstraZeneca PARP inhibitor Lynparza (olaparib) is being explored in clinical trials for thymic epithelial tumors with BRCA mutations, offering personalized treatment options.
MeDiPharm A Korean biopharmaceutical company received Phase 3 trial approval in the US for their novel drug MDN-111 for thymic carcinoma, raising hopes for potential market entry.
List of Thymus Cancer Key Companies in the Market
- Amgen Inc. (US)
- Astellas Pharma Inc. (Japan)
- Eli Lilly and Company (US)
- Merck & Co. Inc. (the US)
- Novartis AG (Switzerland)
- Celgene Corporation (US)
- Pfizer Inc. (US)
- Mylan NV (US)
- Johnson & Johnson Services Inc. (the US)
- Onxeo (France)
- Bristol-Myers Squibb Company (US)
- Boston Biomedical Inc. (the UK)
- AstraZeneca (UK)
- Takeda Pharmaceutical Company Limited (Japan)
- Tiziana Life Sciences plc (UK)
- Teva Pharmaceutical Industries Ltd (Israel)